Finch Therapeutics Group, Inc. (FNCHQ)
Develops oral microbiome drugs to treat autism, inflammatory bowel disease, and other conditions.
$9.97-0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-23.0%
The outlook
FNCHQ is trading near the middle of its 52-week range at $9.97 with a neutral overall score. The stock shows mixed momentum against its moving averages, neither clearly above nor below key technical levels. Analyst coverage appears limited, making consensus views unclear.
What’s behind the score
Price trendMixed vs its moving averages
52-week range57% of the way from its 52-week low to high
Market cap
$16.0M
52-wk high
$16.10
52-wk low
$2.00
50-day avg
$8.87
200-day avg
$11.27
Trailing P/E
—